Envoy Medical Announces Reverse Stock Split
Envoy Medical, Inc. (COCH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Envoy Medical Announces Reverse Stock Split White Bear Lake, Minnesota – October 22, 2026 – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” or the “Company”), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announ
How this was made
The 30-second read
Why it matters
The reverse split is a compliance‑driven corporate action aimed at maintaining Nasdaq listing and may modestly improve share liquidity.
Market read
A micro‑cap corporate action with limited market impact; primarily relevant to current shareholders and potential institutional buyers.
What to watch
Potential dilution from warrant adjustments and cash payments for fractional shares could offset perceived benefits.
Background
Envoy Medical is a Nasdaq‑listed hearing‑health and neuroprosthetics company that recently received FDA Breakthrough Device designation for its Acclaim cochlear implant.
Ticker impact
Envoy Medical filed an 8‑K announcing a 1‑for‑10 reverse stock split effective Oct 26 2026 to meet Nasdaq $1 price requirement.
likely modest upside as price per share increases, but limited long‑term impact.
Reverse splits are typically neutral to bullish; the primary effect is improved liquidity and compliance.
Market effects
May slightly improve perception of Nasdaq‑listed micro‑caps, but no broader sector impact.
Limited to U.S. small‑cap investors; no regional effect.
Minimal global relevance.
Counterpoint
If the split fails to attract new investors, the higher price could reduce liquidity and pressure the stock.
Key entities
- companyEnvoy Medical, Inc.
Nasdaq‑listed hearing‑health device maker (ticker COCH).
